The company has finalized its Phase 3 study protocol, and the trial of mRNA-1273 on about 30K subjects is expected to begin next month.
The primary endpoint of the randomized, placebo-controlled trial will be prevention of symptomatic COVID-19 disease.
Collaborating with Lonza, Moderna (NASDAQ:MRNA) remains on track to be able to deliver about 500M doses per year, and maybe up to 1B doses per year beginning in 2021.
Shares are down 0.95% premarket. Updating at 8:11 AM ET: Shares have now moved into the green, up 2.4% premarket.
https://seekingalpha.com/news/3582229-moderna-moves-forward-phase-3-study-of-covidminus-19-vaccine
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.